APDN Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
September 14, 2023
APDN Advances Commercialization of Linea™ IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
September 6, 2023
APDN Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT™ Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach
July 13, 2023
APDN Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date
March 29, 2023
APDN Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
January 5, 2023
APDN to Establish N. America’s 1st Enzymatic Large-Scale cGMP DNA Manufacturing Capacity in New York
October 24, 2022
LineaRx Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
September 30, 2022
APDN and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications
September 8, 2022
LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)
August 10, 2022
LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development
July 25, 2022
LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit
July 22, 2022
APDN Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website
June 29, 2022
APDN and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy
February 17, 2022
Research Publication Demonstrates Utility of APDN’s LinearDNA™ in Non-Viral CAR T Manufacturing Systems
November 9, 2021
Research Publication Demonstrates Utility of APDN’s LinearDNA™ in Non-Viral CAR T Manufacturing
November 9, 2021
APDN Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch
June 7, 2021
APDN, Evvivax Announce LinearDNA™ Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines
May 6, 2021
APDN, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate
November 30, 2020
APDN Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications
November 2, 2020
APDN and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate
September 16, 2020
APDN Positions LinearDNA™ Platform as the Next Generation Manufacturing Platform for Adeno-Associated Virus-based Gene Therapies Through New Patent Filing
August 17, 2020
APDN and Takis Report Positive Preclinical Results from LineaDNA™ Vaccine Candidates for COVID-19
July 17, 2020
APDN Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates
June 9, 2020
APDN and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals
May 4, 2020
APDN High-Sensitivity and High-Throughput COVID-19 Diagnostic Kit Enters Validation Process in Partnership with Stony Brook University Hospital
April 21, 2020
APDN Ships COVID-19 LinearDNA™ Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing
April 15, 2020
APDN to Speak on COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5
April 14, 2020
APDN Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design a High Sensitivity Diagnostic Kit for Virus Detection
March 19, 2020
APDN COVID-19 Collaboration Partner Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-Clinical Models
March 18, 2020
APDN Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed
March 2, 2020
LineaRx and Takis Biotech Collaborate for Development of a Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV
February 7, 2020
APDN to Hold Investment Community Meetings During the JP Morgan 38th Annual Healthcare Conference and Present at the Biotech Showcase 2020
January 10, 2020
LineaRx Signs Agreement with TYME Technologies for Functional ICTC Assay Services in Pancreatic Cancer Trial
November 26, 2019
LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction
September 19, 2019
LineaRx to Announce DNA Vaccine Preclinical Data and Efficacy of In-Licensed CAR T Therapy
December 4, 2018
LineaRx Licenses CAR T Drug Candidate, Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing Platform
October 16, 2018
LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines
September 20, 2018
LineaRx Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines
September 20, 2018